Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.

Wood ER, Shewchuk L, Hassel A, Nichols J, Truesdale AT, Smith D, Carter HL, Weaver K, Barrett G, Leesnitzer T, Alvarez E, Bardera AI, Alamillo A, Cantizani J, Martin J, Smith GK, Jensen DE, Xie H, Mook R, Kumar R, Kuntz K.

Biochem Pharmacol. 2009 Dec 15;78(12):1438-47. doi: 10.1016/j.bcp.2009.07.022. Epub 2009 Aug 7.

PMID:
19665448
2.

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

Rheault TR, Caferro TR, Dickerson SH, Donaldson KH, Gaul MD, Goetz AS, Mullin RJ, McDonald OB, Petrov KG, Rusnak DW, Shewchuk LM, Spehar GM, Truesdale AT, Vanderwall DE, Wood ER, Uehling DE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):817-20. doi: 10.1016/j.bmcl.2008.12.011. Epub 2008 Dec 7.

PMID:
19111461
3.

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA.

J Med Chem. 2008 Aug 14;51(15):4632-40. doi: 10.1021/jm800566m. Epub 2008 Jul 12.

PMID:
18620382
4.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.

Cancer Res. 2008 Jan 15;68(2):571-9. doi: 10.1158/0008-5472.CAN-07-2404.

5.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M.

Mol Cancer Ther. 2007 Jul;6(7):2012-21.

6.

Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.

Miyazaki Y, Tang J, Maeda Y, Nakano M, Wang L, Nolte RT, Sato H, Sugai M, Okamoto Y, Truesdale AT, Hassler DF, Nartey EN, Patrick DR, Ho ML, Ozawa K.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1773-8. Epub 2006 Dec 24.

PMID:
17276055
7.

Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.

Miyazaki Y, Nakano M, Sato H, Truesdale AT, Stuart JD, Nartey EN, Hightower KE, Kane-Carson L.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):250-4. Epub 2006 Oct 5.

PMID:
17027260
8.

Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.

Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3519-23.

PMID:
15990302
9.

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L.

Cancer Res. 2004 Sep 15;64(18):6652-9.

10.

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Dev IK, Dornsife RE, Hopper TM, Onori JA, Miller CG, Harrington LE, Dold KM, Mullin RJ, Johnson JH, Crosby RM, Truesdale AT, Epperly AH, Hinkle KW, Cheung M, Stafford JA, Luttrell DK, Kumar R.

Br J Cancer. 2004 Oct 4;91(7):1391-8.

11.

4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.

Maeda Y, Nakano M, Sato H, Miyazaki Y, Schweiker SL, Smith JL, Truesdale AT.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):3907-11.

PMID:
15225695
12.

Proteoglycan expression by human trabecular meshworks.

Wirtz MK, Bradley JM, Xu H, Domreis J, Nobis CA, Truesdale AT, Samples JR, Van Buskirk EM, Acott TS.

Curr Eye Res. 1997 May;16(5):412-21.

PMID:
9154378
13.

Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors.

Kiefer LL, Ittoop OR, Bunce K, Truesdale AT, Willard DH, Nichols JS, Blanchard SG, Mountjoy K, Chen WJ, Wilkison WO.

Biochemistry. 1997 Feb 25;36(8):2084-90.

PMID:
9047307
14.

Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line.

Blanchard SG, Harris CO, Ittoop OR, Nichols JS, Parks DJ, Truesdale AT, Wilkison WO.

Biochemistry. 1995 Aug 22;34(33):10406-11.

PMID:
7544613
15.

Adaptive immune defects and delayed rejection of allogeneic tumor cells in beige mice.

Carlson GA, Marshall ST, Truesdale AT.

Cell Immunol. 1984 Sep;87(2):348-56.

PMID:
6467382
16.

Resistance to Moloney murine sarcoma virus-induced tumorigenesis in NK-deficient beige mice.

Truesdale AT, Johnson DA, Bedigian HG, Outzen HC, Carlson GA.

Cell Immunol. 1982 Nov 15;74(1):120-5. No abstract available.

PMID:
7159936

Supplemental Content

Loading ...
Support Center